Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

"Belantamab Mafodotin~Belantamab mafodotin dose levels:~Dose level -2 = 1.4 mg/kg IV every 12 weeks Dose level -1 = 1.9 mg/kg IV every 12 weeks Dose level 0 = 1.9 mg/kg IV every 8 weeks~Cycles 1 - 6:~All patients will start at dose level 0.~Cycles 7 and onwards\*:~Patients previously on dose level 0 (1.9 mg/kg IV every 8 weeks) will change to dose level -1 (1.9 mg/kg IV every 12 weeks) Patients previously on dose level -1 (1.9 mg/kg IV every 12 weeks) will continue at the same dose level.~Patients previously on dose level -2 (1.4 mg/kg IV every 12 weeks) will continue at the same dose level.~\*Reduction to a lower dose level is allowed in case of development of adverse effects or poor tolerance as determined by the treating physician."

"Lenalidomide dose levels:~Dose level 0 (starting dose): Lenalidomide 10 mg/day PO continuously. Dose level -1: Lenalidomide 10 mg/day PO. One week off after every three weeks of treatment.~Dose level -2: Lenalidomide 5 mg/day PO. One week off after every three weeks of treatment."